Jeffrey T. Guptill

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

Medicine, Pharmacology, Pharmacotherapy +6

Anti‐musk antibody myasthenia gravis: Clinical findings and response to treatment in two large cohorts

Jeffrey T. Guptill, Donald B. Sanders, Amelia Evoli · Muscle & Nerve · 2011 · 385 citations

Medicine, Immunology, Internal Medicine +14

A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial

Raffael Nachbagauer, Jodi Feser, Abdollah Naficy et al. · Nature Medicine · 2020 · 358 citations

Veterinary Medicine, Immunology, Infectious Diseases +14

Density and Distribution of Hippocampal Neurotransmitter Receptors in Autism: An Autoradiographic Study

Gene J. Blatt, Claudia M. Fitzgerald, Jeffrey T. Guptill et al. · Journal of Autism and Developmental Disorders · 2001 · 320 citations

Life Sciences, Neurobiology, Neuroscience +13

Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study

James F. Howard, Saskia Bresch, Angela Genge et al. · The Lancet Neurology · 2023 · 250 citations

Medicine, Pharmacotherapy, Pain Management +2